期刊
VIRULENCE
卷 13, 期 1, 页码 1446-1454出版社
TAYLOR & FRANCIS INC
DOI: 10.1080/21505594.2022.2116146
关键词
Rabies virus; interleukin-25; vaccine; adjuvant; virus neutralizing antibodies
资金
- Key Research and Development Program of Guangdong Province [2019B020218004]
- Undergraduate Research Project Nature Science Foundation of Guangdong Province [2018A030313163]
- Nature Science Foundation of Guangdong Province [2022A1515012530]
Rabies is an important zoonotic disease caused by the rabies virus (RABV). Researchers have found that inserting the interleukin-25 (IL-25) gene into the genome of RABV can enhance the immune responses induced by the rabies vaccine, leading to higher levels of virus neutralizing antibodies (VNA). Mice immunized with the recombinant RABV showed a higher survival rate and milder clinical signs after challenge with CVS-11, suggesting that IL-25 can be used as a viral vaccine adjuvant.
Rabies is an important zoonotic disease caused by the rabies virus (RABV). Currently, no effective treatment is available for this condition. The prevention and control of rabies mainly depend on effective vaccination. Therefore, it is crucial to enhance the immune responses induced by the rabies vaccine. Virus neutralizing antibodies (VNA) induced by rabies vaccines are important for the clearance of RABV. Interleukin-25 (IL-25) has been demonstrated to activate T helper type 2 cells that contribute to humoral immune responses. The IL-25 gene was inserted into the genome of RABV, and the immunogenicity of recombinant RABV with IL-25 gene was investigated to develop more efficient rabies vaccines. Here, we found that the expression of IL-25 did not affect RABV production in vitro and pathogenicity in vivo. However, recombinant RABV expression of IL-25 induced a better VNA level than the parental virus in mice. In addition, expression of IL-25 enhanced the IgG1 level induced by RABV. Furthermore, mice immunized with recombinant RABV showed a higher survival rate and milder clinical signs than those immunized with the parent strain after challenge with CVS-11. Thus, these results showed that IL-25 could enhance the humoral immune responses induced by RABV, suggesting that IL-25 can be used as a viral vaccine adjuvant.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据